Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

Abstract Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Supavit Chesdachai, Christina G. Rivera, Kristin C. Cole, Hilary R. Teaford, Maria L. Gonzalez Suarez, Jennifer J. Larsen, Ravindra Ganesh, Sidna Tulledge-Scheitel, Raymund R. Razonable
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-03-01
coleção:	Scientific Reports
Assuntos:	COVID-19 Outcome Remdesivir SARS-2-CoV Sotrovimab
Acesso em linha:	https://doi.org/10.1038/s41598-024-56195-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!